Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
<< anterior 21 a 40 de 47 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Korbonits M, Grossman AB. Drug-induced hyperprolactinaemia. Prescr J 2000;40:157-64. [Ref.ID 52021]
22. Cita con resumen
Zuccato E, Calamari D, Natangelo M, Fanelli R. Presence of therapeutic drugs in the environment. Lancet 2000;355:1789-90. [Ref.ID 51013]
23. Cita con resumen
Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000;49:463-71. [Ref.ID 50715]
24.Tiene citas relacionadas
Knopp RH. Drug treatment of lipid disorders. Dr. Knopp replies. N Engl J Med 1999;341:2021. [Ref.ID 48587]
25.Tiene citas relacionadas
Broeders N, Knoop C, Abramowicz D. Drug treatment of lipid disorders. N Engl J Med 1999;341:2020-1. [Ref.ID 48586]
26.Tiene citas relacionadas
Dorn J, Naughton J, Galletti C. Drug treatment of lipid disorders. N Engl J Med 1999;341:2020. [Ref.ID 48585]
27.Tiene citas relacionadas
Goffin E, Jamar F, Desager JP, Devuyst O. Implication of fibrate therapy for homocysteine. Lancet 1999;354:1209. [Ref.ID 47128]
28.Tiene citas relacionadas
Jonkers IJAM, de Man FHAF, Onkenhout W, van der Laarse A, Smelt AHM. Implication of fibrate therapy for homocysteine. Lancet 1999;354:1208. [Ref.ID 47126]
29. Cita con resumen
Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature. XX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 1999;282:771-8. [Ref.ID 46647]
30.
Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999;354:219-20. [Ref.ID 45998]
31. Cita con resumen
Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999;353:1802. [Ref.ID 45448]
32. Cita con resumen
Collinson HL, Wheeler DC. Drug-induced rhabdomyolysis. Adv Drug React Bull 1999;196:747-50. [Ref.ID 44864]
35. Cita con resumen
Olsen JH, Johansen C, Sorensen HT, McLaughlin J K, Mellemkjaer L, Steffensen FH, Fraumeni JF. Lipid-lowering medication and risk of cancer. J Clin Epidemiol 1999;52:167-9. [Ref.ID 43157]
36.
Gaudy C, Augereau L. Rhabdomyolyses toxiques et iatrogènes: des concepts aux pratiques. Bulletin d'Information du Médicament et de Pharmacovigilance CRIM Rennes 1999;81:1-4. [Ref.ID 43125]
37. Cita con resumen
Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999;57:31-47. [Ref.ID 42328]
38.Tiene citas relacionadas Cita con resumen
Wierzbicki AS, Reynolds T M, Crook MA, Tatler J, Peters B S. Lipid lowering therapy in patients with HIV infection. Lancet 1998;352:1782. [Ref.ID 42120]
39.
Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34:155-62. [Ref.ID 39235]
40.Tiene citas relacionadas Cita con resumen
Braun S, Boyko V, Behar S, Reicher-Reiss H, Laniado S, Kaplinsky E, Goldbourt U, on behalf of the Bezafibrate Infarction Prevention (BIP) Study Research Group. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol 1998;31:804-8. [Ref.ID 38699]
Seleccionar todas
 
<< anterior 21 a 40 de 47 siguiente >>